Compare RJET & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RJET | PHAT |
|---|---|---|
| Founded | 1982 | 2018 |
| Country | United States | United States |
| Employees | 8400 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.0M | 894.0M |
| IPO Year | N/A | 2019 |
| Metric | RJET | PHAT |
|---|---|---|
| Price | $20.12 | $9.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.83 |
| AVG Volume (30 Days) | 174.4K | ★ 1.2M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $93.04 |
| Revenue Next Year | N/A | $58.91 |
| P/E Ratio | $0.21 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $15.37 | $4.25 |
| 52 Week High | $26.70 | $18.31 |
| Indicator | RJET | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 47.12 | 31.78 |
| Support Level | $16.65 | N/A |
| Resistance Level | $21.31 | $12.83 |
| Average True Range (ATR) | 1.94 | 0.72 |
| MACD | 0.03 | -0.26 |
| Stochastic Oscillator | 20.75 | 2.57 |
Republic Airways Holdings Inc is a regional airline mainly in North America. The company provides scheduled passenger service through its mainline partnerships with American Airlines, Delta Air Lines, and United Airlines. Republic offers scheduled passenger service on several daily flights to various cities in the United States, Canada, Mexico, and the Caribbean. It exclusively operates the dual-class Embraer E170/175 family of aircraft, and provides its services under the American Eagle, Delta Connection, or United Express brands. The company is organized and operates as one operating and reportable segment: regional airline services.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.